Pathogenesis of HLH Post-Dengue
Dengue-associated HLH develops through a secondary hyperinflammatory pathway where dengue virus infection triggers uncontrolled activation of macrophages and cytotoxic T cells, leading to a cytokine storm and systemic hyperinflammation that manifests as a severe, potentially fatal syndrome.
Core Pathophysiological Mechanism
The pathogenesis follows the secondary (acquired) HLH pathway rather than the primary genetic form 1. In dengue-associated HLH, the virus acts as an infectious trigger that initiates aberrant immune activation:
- Macrophage dysregulation: Dengue infection causes uncontrolled activation of macrophages and histiocytes, leading to widespread hemophagocytosis (engulfment of blood cells) 2
- Cytotoxic T cell dysfunction: Impaired regulation of cytotoxic T lymphocytes and natural killer (NK) cells results in persistent immune activation 3
- Cytokine storm: The dysregulated immune cells release excessive inflammatory cytokines, creating a self-perpetuating hyperinflammatory state 2
The Common Terminal Pathway
Despite different triggers, all forms of HLH—including dengue-associated cases—converge on a shared hyperferritinemic hyperinflammatory syndrome with a common terminal pathway 1. This explains why dengue-associated HLH presents similarly to other secondary HLH forms, with:
- Uncontrolled lymphocyte and histiocyte proliferation
- Massive cytokine release (particularly interferon-gamma, TNF-alpha, IL-6)
- Systemic inflammation affecting multiple organ systems
- Hemophagocytosis in bone marrow and other tissues
Clinical Manifestation of the Pathophysiology
The underlying pathogenesis translates into specific clinical and laboratory findings that distinguish dengue-associated HLH from uncomplicated dengue 4, 5:
Prolonged immune activation markers:
- Fever persisting >7 days (median 10 days vs. 5-6 days in uncomplicated dengue) 4, 6
- Progressive cytopenias beyond the typical dengue critical phase 7
Tissue damage from hyperinflammation:
- Severe hepatitis with markedly elevated transaminases (AST >4000 U/L) 4
- Myocarditis in two-thirds of cases 4
- Hepatosplenomegaly from histiocyte infiltration 6, 7
Laboratory evidence of immune dysregulation:
- Extreme hyperferritinemia (>3000 ng/mL) 7
- Hypertriglyceridemia (>300 mg/dL) 4
- Elevated soluble CD25 (>3000 pg/mL) 4
- Coagulopathy beyond typical dengue (prolonged PT/PTT) 4
Risk Factors and Susceptibility
Certain patient characteristics increase vulnerability to developing HLH following dengue infection 5:
- Young age: Infants and children <2 years are disproportionately affected (median age 1 year in cases vs. 13 years in controls)
- Co-infections: Bacterial co-infections or recent influenza-like illness increase risk 4-fold
- Immune priming: Recent febrile illness may predispose to exaggerated immune response
Critical Clinical Pitfall
The most dangerous pitfall is assuming persistent fever and worsening cytopenias after day 7 represent complicated dengue alone, rather than recognizing this as the hallmark presentation of dengue-associated HLH 6, 7. The pathophysiology has shifted from viral-mediated disease to immune-mediated hyperinflammation, requiring fundamentally different treatment (immunosuppression rather than supportive care alone).
The mortality rate of dengue-associated HLH reaches 26% when unrecognized 4, but drops to 4.5% with appropriate identification and treatment 5, emphasizing that understanding this pathophysiological transition is life-saving.
Epidemic Clustering Pattern
Notably, dengue-associated HLH cases cluster during major dengue epidemics 5, suggesting that high viral loads, specific circulating serotypes, or healthcare system strain during outbreaks may contribute to the pathogenesis, though the exact mechanism remains unclear. Both DENV-1 and DENV-4 have been implicated without clear serotype predominance 5.